INTRODUCTION {#s1}
============

Oral cavity cancer is the most common head-and-neck cancer, which accounts for approximately 3% of all newly diagnosed cancer cases \[[@R1], [@R2]\]. Most oral cavity cancers are oral cavity squamous cell carcinomas (OSCCs), which are locally aggressive and show moderate locoregional recurrence and survival rates \[[@R3]--[@R5]\]. Despite modern improvements in the treatment modalities, which include surgery, radiotherapy and chemotherapy, the 5-year overall survival rate of OSCC patients is only \~ 60% \[[@R6]--[@R8]\]. OSCC can arise from various locations in the oral cavity, including the tongue, buccal area, gingiva, lip, floor of mouth, and hard palate. The disease develops from precancerous dysplastic lesions through multistep processes of carcinogenesis that usually involves chronic exposure to carcinogens (e.g., tobacco exposure, alcohol intake, and inflammation) \[[@R9]--[@R12]\]. In Taiwan, alcohol, betel nut chewing and smoking are considered to be the major risk factors for OSCC. These factors have been shown to induce NLRP3 inflammasome activity and/or IL-1β activation in other cell types and diseases \[[@R13]--[@R15]\], but the role of the NLRP3 inflammasome in OSCC has not yet been explored.

Apoptosis-associated Speck-like protein containing a CARD domain \[ASC; also called PYD and CARD domain-containing protein (PYCARD), [t]{.ul}arget of [m]{.ul}ethylation-induced [s]{.ul}ilencing (TMS1) \[[@R16]\], is the platform protein of inflammasomes. It plays a key role in activating the inflammasome \[[@R17]\] by interacting via its PYD domain with pattern recognition receptors (e.g., NLRP3), and via its CARD domain with pro-caspase-1, leading to caspase-1 activation; this inflammasome activation promotes maturation of the cytokines, IL-1β and IL-18 \[[@R18]\]. The maturation of IL-1β by an activated inflammasome is an important mechanism for tumor pathogenesis in melanoma \[[@R19]\], colorectal cancer \[[@R20], [@R21]\], and nasopharyngeal carcinoma (NPC) \[[@R22]\]. Indeed, accumulating information suggests that ASC may play multiple roles in cancer. For example: it can function as a tumor suppressor; its expression is decreased by promote methylation in cancers such as melanoma \[[@R23]\], breast cancer \[[@R24]\], ovarian cancer \[[@R25]\], prostate cancer \[[@R26]\], colorectal cancer \[[@R27]\] and hepatocellular carcinoma \[[@R28]\]; it is reportedly involved in the progression of melanoma \[[@R29]\]; and our group showed that it is highly elevated in NPC tumor cells, where its expression correlates with local recurrence and the survival of patients \[[@R22]\]. These findings prompted us to explore the potential role of inflammasome proteins in OSCC, which is believed to be associated with local inflammation.

Here, we demonstrate for the first time that NLRP3 and its inflammasome-associated proteins, ASC, IL-1β, and CASP1, are highly expressed in OSCC tumor tissues, as examined by immunohistochemistry (IHC), Western blot and RT-qPCR analyses. We also demonstrate that high-level expression of ASC (but not the other three proteins) was significantly associated with various clinicopathological characteristics (*p*\<0.001) and was correlated with poorer patients\' survival (*p*\<0.001). *In vitro* studies using OSCC cell lines and *in vivo* lymph node metastasis model of oral squamous cell carcinoma confirmed that ASC induced OSCC cell metastasis.

RESULTS {#s2}
=======

Overexpression of inflammasome genes in OSCC tumor tissues {#s2_1}
----------------------------------------------------------

We examined the expression of NLRP3 inflammasome-related components in 20 OSCC tumors and adjacent normal tissues using microarray analysis \[[@R30]\] ([Supplementary Table S2](#SD1){ref-type="supplementary-material"} and Figure [1A](#F1){ref-type="fig"}), followed by RT-qPCR validation in an independent group of samples (n=20). RT-qPCR revealed that the expression levels of all four tested NLRP3 inflammasome-associated genes (*asc, casp1, il-1b*, and *nlrp3*) were highly elevated in the 20 OSCC tissues, by 1.89-fold, 1.7-fold, 46.31-fold and 3.76-fold, respectively (Figure [1B](#F1){ref-type="fig"}). We next used immunohistochemical (IHC) staining to evaluate the protein expression levels of ASC, IL-1β, CASP1 and NLRP3 in tumor cells using a second cohort of OSCC biopsy samples (n=111). Our results confirmed that these proteins were highly expressed in OSCC tumor cells, but were only weakly expressed in adjacent normal cells (Figure [1C](#F1){ref-type="fig"}). Clinical details on the enrolled patients are shown in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. Together, our results show that the NLRP3 inflammasome-related molecules are overexpressed in OSCC.

![Inflammasome proteins are highly expressed in OSCC\
**A.** Microarray results for NLRP3 inflammasome-associated proteins. **B.** Relative mRNA expression levels of *asc*, *il-1b*, *casp1*, and *nlrp3* in tumor (T) and adjacent normal tissues (N). **C.** ASC, IL-1β, CASP1, and NLRP3 proteins are overexpressed in the tumor regions (T) compared to adjacent normal regions (N) of OSCC clinical samples. Magnification, X400; bar, 50 μm. **D.** Kaplan-Meier survival analysis of OSCC patients. The overexpressions of ASC, IL-1β, and CASP1 (but NLRP3) are associated with poor prognoses for OS (upper), DSS (middle) and DFS (lower). ASC positive (+), n=54; ASC negative (-), n=57; IL-1β positive (+), n=35; IL-1β negative (-), n=76; CASP1 positive (+), n=50; CASP1 negative (-), n=61.](oncotarget-07-50074-g001){#F1}

Associations of ASC, IL-1β and CASP1 with clinicopathological manifestations {#s2_2}
----------------------------------------------------------------------------

To investigate the potential clinical significance of the NLRP3 inflammasome in OSCC, we analyzed the associations of our IHC staining scores with the patients\' clinicopathological characteristics. As shown in Table [1](#T1){ref-type="table"}, high-level expression of ASC was significantly correlated with many clinicopathological characteristics, including tumor stage (*p*\<0.001), node stage (*p*\<0.001), overall stage (*p*\<0.001), extracapsular spread (*p*\<0.001), perineural invasion (*p*=0.004) and tumor depth (*p*\<0.001). In addition, high-level expression of IL-1β was correlated with age (*p*=0.024) and overall stage (*p*=0.023); high-level expression of CASP1 was correlated with node stage (*p*=0.041), overall stage (*p*=0.006) and perineural invasion (*p*=0.013); and high-level expression of NLRP3 was correlated with extracapsular spread (*p*=0.020) and perineural invasion (*p*=0.013). These results indicate that ASC, IL-1β, CASP1, and NLRP3 are all highly associated with the clinicopathological characteristics of OSCC, and that ASC is significantly associated with all of the examined clinicopathological manifestations.

###### Association of expression levels (immunohistochemical score) of three proteins increasing in the OSCC tumors with clinicopathological characteristics in 111 untreated OSCC patients

                                                        No.   ASC      IL1β      CASP1    NLRP3                             
  ----------------------------------------------------- ----- -------- --------- -------- ------- -------- ------- -------- -------
  **Gender**                                                                                                                
   Female                                               14    107±55   0.234     111±58   0.809   112±47   0.311   160±40   0.264
   Male                                                 97    127±36             118±33           129±34           147±47   
  **Age (yr)[†](#tfn_002){ref-type="table-fn"}**                                                                            
   \<49.5                                               55    120±35   0.139     111±35   0.024   127±34   0.760   151±46   0.760
   \>49.5                                               56    129±43             123±38           127±39           146±46   
  **Tumor stage**                                                                                                           
   1-2                                                  65    114±40   0.001     115±41   0.274   123±38   0.075   151±52   0.323
   3-4                                                  46    138±34             123±30           133±33           145±37   
  **Node stage**                                                                                                            
   (-)                                                  66    109±38   \<0.001   112±37   0.132   121±36   0.041   149±46   0.798
   (+)                                                  45    146±30             125±36           136±35           148±46   
  **Overall stage**                                                                                                         
   I-II                                                 42    100±36   \<0.001   106±39   0.023   115±36   0.006   147±52   0.910
   III-IV                                               69    139±34             124±34           134±34           149±42   
  **Extracapsular spread**                                                                                                  
   No                                                   87    118±38   \<0.001   114±36   0.139   124±35   0.158   153±45   0.020
   Yes                                                  24    148±37             129±37           137±37           130±46   
  **Perineural invasion**                                                                                                   
   No                                                   77    117±40   0.004     113±35   0.212   121±36   0.013   154±50   0.013
   Yes                                                  34    142±31             128±40           140±34           135±34   
  **Tumor depth^[†](#tfn_002){ref-type="table-fn"}^**                                                                       
   \<=8                                                 58    110±38   \<0.001   113±39   0.194   121±35   0.193   153±53   0.102
   \>8                                                  53    140±34             122±34           133±37           144±37   

Mean±SD;

Median

Associations of ASC, IL-1β and CASP1 overexpression with patient overall survival (OS), disease specific survival (DSS) and disease free survival (DFS) {#s2_3}
-------------------------------------------------------------------------------------------------------------------------------------------------------

We further evaluated whether the overexpression of ASC, IL-1β, CASP1, and/or NLRP3 was correlated with patients\' OS, DSS, and DFS (Figure [1D](#F1){ref-type="fig"}). Survival analysis using Kaplan-Meier plots for high expression of ASC, IL-1β and CASP1 patients versus low expression of ASC, IL-1β and CASP1 patients, respectively. We revealed that the 5-year OS rates for the stratified patients with high expression of ASC, IL-1β and CASP1 were 84.5% versus 49.8% in ASC, 72.1% versus 54.1% in IL-1β, and 73.9% versus 57.1% in CASP1, respectively (*p*=0.0001, 0.045, and 0.041, respectively, by log-rank test); the 5-year DSS rates stratified patients with ASC, IL-1β and CASP1 were 86.0% versus 49.7% in ASC, 73.1% versus 54.1% in IL-1β, and 73.9% versus 58.2% in CASP1, respectively (*p*\<0.0001, =0.031, and =0.059, respectively, by log-rank test); and the 5-year DFS rates stratified patients with ASC, IL-1β and CASP1 were 80.4% versus 44.8% in ASC, 68.4% versus 48.2% in IL-1β, and 71.3% versus 50.4% in CASP1, respectively (*p*\<0.0001, =0.027, and =0.021, respectively). In contrast, NLRP3 overexpression was not found to correlate with survival (Figure [1D](#F1){ref-type="fig"}).

We next performed multivariate analysis using age, gender, overall stage, perineural invasion, and overexpression of the four target proteins as parameters in a Cox proportional regression model. Our results further indicated that upregulation of ASC was an independent predictor of OS, DSS, and DFS (*p* = 0.026, 0.013, and 0.042, respectively), whereas the other tested proteins were not found to predict these parameters (Table [2](#T2){ref-type="table"}).

###### Multivariate analysis on overall survival, disease-specific survival, and disease-free survival of patients with squamous cell carcinoma after treatment

  Characteristics            Overall survival        Disease-specific survival                 Disease-free survival                                                                 
  -------------------------- ----------------------- ----------------------------------------- ----------------------- ----------------------------------------- ------------------- -----------------------------------------
  ASC overexpression                                                                                                                                                                 
   Yes                       1.000 (Reference)       0.026[†](#tfn_004){ref-type="table-fn"}   1.000 (Reference)       0.013[†](#tfn_004){ref-type="table-fn"}   1.000 (Reference)   0.042[†](#tfn_004){ref-type="table-fn"}
   No                        2.510 (1.116 − 5.646)   2.935 (1.251 − 6.886)                     2.153 (1.026 − 4.519)                                                                 
  IL-1β overexpression                                                                                                                                                               
   Yes                       1.000 (Reference)       0.367                                     1.000 (Reference)       0.264                                     1.000 (Reference)   0.464
   No                        1.411 (0.668 −2.984)    1.547 (0.719 −3.330)                      1.303 (0.641 −2.649)                                                                  
  Caspase 1 overexpression                                                                                                                                                           
   Yes                       1.000 (Reference)       0.110                                     1.000 (Reference)       0.141                                     1.000 (Reference)   0.097
   No                        1.806 (0.874 −3.732)    1.738 (0.833 −3.628)                      1.795 (0.899 −3.585)                                                                  
  NRLP3 overexpression                                                                                                                                                               
   No                        1.000 (Reference)       0.380                                     1.000 (Reference)       0.446                                     1.000 (Reference)   0.242
   Yes                       0.684 (0.293 −1.599)    0.717 (0.305 −1.687)                      0.618 (0.275 −1.386)                                                                  

Median age is 49.5 y;

statistically significant

ASC contributes to the migration and invasion of OSCC cells {#s2_4}
-----------------------------------------------------------

Since ASC was overexpressed in OSCC tumor cells, and this overexpression was highly associated with OSCC metastasis, we tested the effect of ASC protein overexpression/knockdown on the cell migration and invasion of OSCC cell lines *in vitro*. In SAS cells, ASC was overexpressed or knocked down by transfection with an ASC-expressing vector or an ASC-targeting siRNA, respectively, as confirmed by Western blot analysis (Figure [2A](#F2){ref-type="fig"} and Figure [2B](#F2){ref-type="fig"}). These alterations in the expression level of ASC did not affect the cell growth rate, as demonstrated in Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}. However, the migration and invasion abilities were 2.3-and 6-fold higher in ASC-overexpressing cells compared to cells transfected with the vector control (Figure [2C](#F2){ref-type="fig"}). Moreover, ASC-knockdown SAS cells showed significant inhibitions of cell migration and invasion (both by \~75%) (Figure [2D](#F2){ref-type="fig"}). Similar results were also observed when we overexpressed ASC in low-expressing OECM1 cells ([Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}) or knocked down ASC in high-expressing OC3 cells ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}). Enhanced cell migration and invasion were observed in ASC-overexpressing OECM1 cells ([Supplementary Figure S1C](#SD1){ref-type="supplementary-material"}), whereas reductions of 30% and 60% were seen in the migration and invasion abilities, respectively, of ASC-knockdown OC3 cells ([Supplementary Figure S1D](#SD1){ref-type="supplementary-material"}). Together, these data indicate that ASC enhances the cell migration and invasion abilities of OSCC cell lines.

![ASC promotes migration and invasion ability in OSCC cell lines\
**A** and **B.** Cell proliferation assays were performed on SAS cells overexpressing ASC or the control vector (A) or transiently transfected with control or ASC-targeting siRNAs (B) Western blot results show the expression levels of ASC in the SAS cells. **C.** Migration and invasion assays of ASC-overexpressing SAS cells show 2.3- and 6-fold increases in cell migration (top) and invasion (bottom), respectively. **D.** Migration and invasion assays of ASC-knockdown cells show \~75% decreases in migration (top) and invasion (bottom) compared with the vector control.](oncotarget-07-50074-g002){#F2}

ASC promotes lymph node metastasis in nude mice {#s2_5}
-----------------------------------------------

As our clinical observations have suggested that ASC could be associated with lymph node metastasis, we generated SAS cells that stably overexpressed ASC (SAS_Luc2_ASC) or vector control (SAS_Luc2), used them to inoculate nude mice, and examined ASC-associated metastasis in an oral cancer (tongue) model (Figure [3A](#F3){ref-type="fig"}; for details, see Materials and Methods). Nude mice were inoculated with SAS_Luc2 or SAS_Luc2_ASC cells (n=5, respectively), and tumor formation and lymph node metastasis were examined on days 8, 15 and 22, using an *in vivo* imaging system (Figure [3B](#F3){ref-type="fig"}). In three independent experiments, we found the metastasis rate is higher in SAS_Luc2_ASC mice than in SAS_Luc2 mice (*p*=0.033) (Figure [3C](#F3){ref-type="fig"}). Anatomy result demonstrated that the tumor cells metastasized to the cervical-region lymph nodes of mice injected with SAS_Luc2_ASC cells (Figure [3D](#F3){ref-type="fig"}). IHC staining confirmed that ASC was overexpressed in tongue and lymph node sections from mice carrying SAS_Luc2_ASC tumors but not in those obtained from SAS_Luc2 control mice (Figure [3E](#F3){ref-type="fig"}). In terms of mortality, the SAS_Luc2 and SAS_Luc2_ASC groups respectively experienced the deaths of one and four mice by day 15, and five and two additional mice by day 22 (these mice were examined for tumor metastasis at death and included in our analysis). These results suggest that ASC-overexpressing tumor cells may have enhanced potential for metastasis.

![ASC promotes tumor metastasis in an animal model\
**A.** Design of the animal study. **B.** The IVIS visualization system used to track tumor growth and metastasis. Mice were inoculated with SAS_Luc2 or SAS_Luc2_ASC on day 1, and images were monitored and recorded on days 8, 15 and 22. Red arrows indicate the metastatic lymph node. **C.** Comparison of metastatic lymph node between SAS_Luc2 and SAS_Luc2_ASC mice, data shown as mean±SE from 3 independent experiments; 5 mice were tested in each group for each experiment (*p*=0.033). **D.** Image of lymph node metastasis in the cervical region of a SAS_Luc2\_ ASC mouse. Red arrows indicate the metastatic lymph node. **E.** Histological image of tongue and lymph nodes sections in four representing SAS_Luc2_ASC-carrying mice, and in two SAS_Luc2 control mice as described in Results. ASC is highly expressed in SAS_Luc2_ASC mice, but not in SAS_Luc2 mice. Magnification, X200; bar, 100μm.](oncotarget-07-50074-g003){#F3}

DISCUSSION {#s3}
==========

Here, we show that the NLRP3 inflammasome-related proteins, ASC, IL-1β, CASP1, and NLRP3, are all highly expressed in OSCC tumor cells compared to adjacent normal cells. Of them, ASC was significantly correlated with various clinicopathological characteristics (Table [1](#T1){ref-type="table"}), including node stage, overall stage \[[@R31]\], extracapsular spread, and perineural invasion, and was an independent predictor of OS, DSS, and DFS for OSCC patients (Table [2](#T2){ref-type="table"}). *In vitro* and *in vivo* studies further demonstrated that ASC appears to promote tumor metastasis. These results are highly consistent with clinical observations of OSCC examined in this study. Above all, overexpression of ASC in OSCC is highly positively correlated with OSCC tumor progression. To our knowledge, this is the first report to show that ASC has oncogenic activity in OSCC.

In this context, ASC gene expression is reportedly down-regulated through DNA methylation of its promoter, mainly within the region spanning nts −146 to +246. In contrast to the prior reports, we herein found that ASC was overexpressed in OSCC tumor tissues. We examined the DNA methylation status of the ASC gene promoter within this region by bisulfide sequencing in two paired OSCC/normal adjacent biopsies, which showed high ASC expression by IHC. As presented in [Supplementary Figure S2A](#SD1){ref-type="supplementary-material"}, we confirmed that the 37 CpG sites within the nts −146 to +246 region of the ASC gene promoter were unmethylated. In addition, Western blot analysis confirmed that ASC was more highly expressed in the tumor tissues compared to the paired adjacent normal tissues ([Supplementary Figure S2B](#SD1){ref-type="supplementary-material"}). IHC staining of the 111 paired OSCC samples revealed that only two failed to show expression of ASC. Moreover, ASC overexpression in tumor cells was also detected in Epstein-Barr virus-associated NPC \[[@R22]\]. Further studies will be needed to determine the mechanism(s) responsible for regulating ASC expression in OSCC.

In this study, high level of ASC expression in OSCC specimens predicted poorer prognosis of patients, which is different from a previously report by Shimane *et al.* \[[@R31]\]. The difference can be resulted from the following reasons. First, the scoring methods used in our study and their study were different. In our study, the scores for each IHC specimens were multiplied by the percentage of cells that showed positive staining, and the scores reflected protein expression (Materials and methods). The resulting scores were used to classify the specimens/patients into two groups: 'high-level' protein expression and 'low-level' protein expression. For ASC, scores ≤120 was defined as low level, scores \>120 defined as high level. For the other study, the scoring method of IHC results to classify specimens was based on the intensity of anti-ASC antibody alone, and specimens were classified into level 1, 2 or 3. Second, another difference may be due to the age distribution of patients; the average age of OSCC was 49.5 years old and the ratio of male:female was 7:1, reflecting the age and gender distribution of OSCC in Taiwan, whereas the average age was 65 years old and male: female ratios was 1.3:1 in that study.

Inflammasome activation has been reported in many kinds of cancer, including liver cancer \[[@R32]\], gastric cancer \[[@R33]\], NPC \[[@R22]\] and melanoma \[[@R29]\]. However, no study to date has investigated the potential involvement of inflammasome activity in OSCC. Our microarray data and RT-qPCR results revealed that other pattern recognition receptors, such as AIM2 and RIG-I, also showed elevated expression in OSCC tumor tissues (data not shown). The microbiome including bacteria species in oral cavity are altered in tumor and non-tumorous tissues as revealed by the next generation sequencing studies \[[@R34], [@R35]\]. Thus, microorganisms or their products may activate cells to generate hydrogen peroxide, which in turn activates NLRP3 inflammasome, and to induce DNA damage to activate AIM2 inflammsome in epithelial cells \[[@R36]\]. Using OSCC cell lines, NLRP3 and other inflammasomes can be induced, suggesting of activated inflammsomes in OSCC (data not shown) by factors in microenvironement. These results indicated that inflammasome activity may be induced by pathogens in OSCC. Inflammasome activation has been reported in other pathogen-related cancers, such as in HCV-associated liver cancer \[[@R37]\], *Helicobacter*-associated gastric cancer \[[@R33]\] and EBV-associated NPC \[[@R22]\]. In oral cancer, HPV and few oral bacteria are thought to be related to OSCC progression \[[@R34], [@R38], [@R39]\]. However, we do not yet know if these pathogens induce inflammasome activation, and if so, whether this inflammasome activation is associated with OSCC. Smoking and betel quid chewing have been strongly associated with OSCC progression in Taiwan \[[@R40]\]. However, we observed that neither nicotine nor arecoline triggered inflammasome activation, as assessed by measuring the level of secreted IL-1β (data not shown). Considering the diversity and complexity of the microbes found in oral saliva \[[@R34]\], other factors or combinations of multiple factors may be involved in OSCC.

In *in vivo* oral metastasis experiment, we recorded the IVIS data of all experimental mice, but we were unable to collect tongue, lymph node, lung and liver specimens from mice those died during the experiment. To determine lymph node metastasis of tumor, we performed the IHC analysis using anti-ASC antibody on tongue, lymph node, lung and liver specimens from the IVIS-positive mice. For subject No.14 (Figure [3A](#F3){ref-type="fig"} at d22), IVIS was negative but IHC showed positive result ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). In addition, we did not observe lung or liver metastasis in these mice (data not shown). There was no significant difference in survival rate between SAS_Luc2 mice and SAS\_ Luc2_ASC mice (data not shown). Thus, tumor-related *in vivo* results here support that ASC promotes metastasis of OSCC cells.

In this study, only ASC, but not the other inflammasome-associated molecules NRLP3, CASP1 and IL-1β was strongly associated with the clinicopathological characteristics (e.g. tumor stage and node stage) and was an independent predictor of OS, DSS, and DFS of OSCC patients. In *in vitro* and *in vivo* studies, ASC induced cell migration and invasion as well as induced metastasis in mice. We have tested the effect of ASC on E-cadherin, a key epithelial-mesenchymal transition (EMT) gene (unpublished results). We found that E-cad gene expression were decreased 65% in SAS_Luc2_ASC cells compared to SAS_Luc2 cells using qRT-PCR analysis. This result indicates that ASC may mediate cell migration and invasion through regulating EMT genes such as E-cadherin. We are currently planning additional studies to explore the molecular mechanism(s) underlying the ASC-mediated promotion of metastasis in OSCC.

In summary, we herein use clinical samples, cell lines and *in vivo* studies to show that ASC can act as a potential biomarker of metastasis in OSCC. Recently, small molecule inhibitors have been developed against ASC \[[@R41]\]. Given our present findings, we propose that ASC may be a potential oncotarget for OSCC therapy.

MATERIALS AND METHODS {#s4}
=====================

Cell culture {#s4_1}
------------

The SAS cell line (Bioresource Collection and Research Center, Taiwan) was maintained in DMEM supplemented with 10% fetal bovine serum (FBS). OC3 cells derived from buccal epidermal carcinoma \[[@R42]\] were maintained in keratinocyte serum-free medium (Invitrogen, Carlsbad, CA, USA) and DMEM/10% FBS (2:1 ratio). OECM1 cells derived from gingival epidermal carcinoma \[[@R43]\] were maintained in RPMI supplemented with 10% FBS. All three cell lines were obtained from Professor Jau-Song Yu in Graduate Institute of Biomedical Sciences, Chang Gung University, Tao-Yuan, Taiwan.

Patient information {#s4_2}
-------------------

Clinical samples were obtained from a consecutive cohort of 111 OSCC patients for IHC analysis and 20 OSCC patients for RT-quantitative PCR exam diagnosed at the Chang Gung Memorial Hospital (Tao-Yuan, Taiwan) from August 2002 to June 2007. OSCC patients presenting with unresectable disease, synchronous cancers, distant metastasis, or any previous history of malignancy were excluded. All patients provided informed consent prior to their participation, and this study was approved by the Institutional Review Board. According to the institution\'s guidelines, each patient underwent a standard preoperative work-up that included a detailed medical history, a complete physical examination, computed tomography or magnetic resonance imaging scans of the head and neck, chest radiographs, a bone scan, and an abdominal ultrasound. Primary tumors were intraoperatively excised with adequate margins under frozen-section control. Classic radical or modified neck dissection (levels I--V) was performed in patients with clinically positive lymph node disease. Supraomohyoid neck dissection (levels I--III) was performed in clinically node-negative patients \[[@R44]\]. When necessary, surgical defects were immediately reconstructed by plastic surgeons using free or local flap techniques. The pathological and nodal stages of all tumors were established as described in the AJCC Cancer Staging Manual (2010). Post-operative radiotherapy was performed within 6 weeks following surgery on patients with pathologic T4 tumors and positive lymph nodes. Patients with pathologic evidence of multiple neck lymph node metastasis and/or extracapsular spread received concurrent adjuvant chemoradiotherapy (a cisplatin-based regimen plus a total radiation dose of 66 Gy given as 1.8-2 Gy per day for 5 days per week). After discharge, all patients had regular follow-up visits every 2 months for the first year, every 3 months for the second year, and every 6 months thereafter \[[@R45], [@R46]\].

Bisulfite sequencing {#s4_3}
--------------------

Genomic DNA (2μg) was modified by sodium bisulfite using an EZ DNA methylation kit (Zymo Research, USA). The promoter region of *asc* from nts −146 to +246 (containing 37 CpG dinucleotide sites) was amplified with specific primers (5′-TTA GGT AGA AGT TGA TTA GTT TGT-3′ and 5′-CCA AAA ACC TAA ATA AAA AAA A-3′). The PCR products were cloned into the TA vector (YEASTERN BIOTECH. CO., LTD) and sequenced. The sequencing results were analyzed using Vector NTI 9.0 software (Invitrogen, USA).

Immunohistochemical staining of OSCC specimens {#s4_4}
----------------------------------------------

IHC analyses were performed using a Bondmax automated immunostainer (Bond, Vision BioSystems) according to the manufacturer\'s instructions. An anti-ASC antibody (1:100; MBL International Corporation) was used to detect ASC in clinical tissue sections and mouse tongues and lymph nodes. Standard staining and IHC scoring methods were used, as previously described \[[@R22]\]. Briefly, IHC intensity was divided into four graded as 0, 1, 2, or 3 to indicate undetectable, weak, moderate, and strong staining, respectively. The scores for each IHC specimens were multiplied by the percentage of cells that showed positive staining, and the scores reflected protein expression. The resulting scores were used to classify the specimens/patients into two groups: 'high-level' protein expression and 'low-level' protein expression. For ASC, scores ≤120 was defined as low level, scores \>120 was defined as high level; for CASP1, score ≤100 was low level, and \>100 was high level; for IL-1β, score ≤40 was low level, and \>40 was high level; for NLRP3, score ≤160 was low, and \>160 was high.

Lentivirus construction and establishment of stable clones {#s4_5}
----------------------------------------------------------

Three functional plasmids were used, as follows: (1) pLKO.AS2.neo/pLKO.AS2.ASC (1 μg), representing the control and ASC-overexpressing vectors, (2) helper plasmid pCMV-ΔR8 (0.9 μg), which expressed the viral *gag* and *pol* genes, and (3) envelope plasmid pMD.G (0.9 μg). Lentiviruses were constructed according to the provided protocol and co-transfected into HEK293 cells for packaging (the National RNAi Core Facility of Academia Sinica). To establish a stably transfected clone, SAS cells were transfected with ready-to-use lentiviruses containing a firefly luciferase 2 (Luc2) reporter gene \[[@R47]\] and infected with pLKO.AS2.neo or pLKO.AS2.ASC lentivirus in 6 μg/ml of Polybrene (Sigma-Aldrich) and selected with 400 μg/ml Geneticin (Life Technologies) and 2 μg/ml puromycin (Life Technologies). The selected clones SAS_Luc2 and SAS_Luc2_ASC were subjected to cell proliferation assays and used for our animal studies.

RNA extraction and RT-quantitative (q)PCR {#s4_6}
-----------------------------------------

Total RNA was isolated from the oral cancer cell lines using the TRIZOL reagent (Invitrogen) and cDNA was generated with SuperScript III (Invitrogen) according to the manufacturer\'s protocol. Real-time qPCR was performed using Light-cycler (Roche). The expression of GAPDH was monitored as an internal control. The examined genes and primers used in this study were described as below: *il-1b*, 5′-TCT CCG ACC ACC ACT AC-3′ and 5′-AGC CTC GTT ATC CCA T-3′; *asc*, 5′-ATC CAG GCC CCT CCT CAG T-3′ and 5′-GTT TGT GAC CCT CGC GAT AAG-3′; *casp1*, 5′-GAA TGT CAA GCT TTG CTC CCT AGA-3′ and 5′- AAG ACG TGT GCG GCT TGA CT-3′; *nlrp3*, 5′-TCT GTG TGT GGG ACT GAA GCA-3′ and 5′-TAC TGA TGC AAG ATC CTG ACA ACA-3′.

Cell proliferation assay {#s4_7}
------------------------

SAS (2×10^5^) or OECM1 (2×10^5^) cells were seeded to six-well culture plates and transiently transfected with plasmids pLKO.neo.AS2 or pLKO.neo.AS2.ASC for ASC-overexpression studies; with scrambled or ASC-targeting siRNAs (Dharmacon, GE) for ASC knockdown studies. Cell numbers were counted daily for 4 days. Each test was performed in duplicate at least three independent times.

Trans-well migration assay {#s4_8}
--------------------------

Trans-well migration assays were performed in a 24-well Trans-well chamber (Corning, USA) fitted with a polycarbonate membrane (8-μm pore size), as previously described \[[@R48]\]. Briefly, SAS (1×10^5^), OECM1 (1×10^5^) or OC3 (2×10^5^) cells were washed two or three times with serum-free medium, re-suspended in 100 μl of serum-free medium, and seeded to the upper chamber. The lower chamber was loaded with medium containing 10% FBS, and the plates were cultured for 16 hours under 5% CO~2~ at 37°C. The migrated cells attached on the chamber membrane were fixed and stained with 0.25% crystal violet, 10% formaldehyde and 80% methanol for 15 minutes, and then washed five times with ddH~2~O. The migrated cells were enumerated by averaging the counts obtained from 10 random microscopic fields under 100× magnification. The test was performed three independent times.

Cell invasion {#s4_9}
-------------

Invasion assays were performed using a Chemicon cell invasion assay kit (ECM550; Millipore, MA, USA). Briefly, the ECM layer in the insert (8-μm pore size) was rehydrated in serum-free medium (300μl) for 2 hours at room temperature. The medium was then replaced with 300μl serum-free medium containing 1×10^6^ cells. Medium containing 10% FBS was added to the lower chamber, and the cells were incubated at 37°C under 5% CO~2~ for 24 hours. The non-invaded cells were gently removed with a cotton swab, and the invaded cells were fixed and stained for 15 minutes with 0.25% crystal violet, 10% formaldehyde and 80% methanol. The non-adherent cells were removed by five washes with ddH~2~O, and the remaining cells were counted and averaged from 10 random microscopic fields (100× magnification). The test was performed three independent times.

Animal study {#s4_10}
------------

Nude mice (8 to 12 weeks old) were obtained from National Laboratory Animal Center. For animal study, we have performed three independent experiments; 5 mice were inoculated with SAS_Luc2 control cells and 5 mice were inoculated with SAS_Luc2_ASC cells in each experiment. We then analyzed the number of mice with lymph node metastasis in control vs. ASC-expressing group from each experiment, independently. The statistical significance was determined by student *t* test between these two groups. Briefly, SAS_Luc2 and SAS_Luc2_ASC cell lines (2.5×10^5^ in 40 μl serum-free DMEM) were inoculated into the tip of the mouse tongue \[[@R49]--[@R51]\]. Tumor progression was monitored once a week, using an IVIS Spectrum (Xenogen IVIS 100; Caliper) \[[@R47]\]. Twenty-two days later, mice were sacrificed, and tongue and cervical region lymph nodes were subjected to IHC examination using anti-ASC antibody.

Statistical analysis {#s4_11}
--------------------

All statistical data are expressed as means ± SD. The Wilcoxon signed ranks test was used to compare the relative signal intensities (IHC staining scores) of paired tumor and pericancerous normal epithelium samples. Cell proliferation, migration, invasion and lymph node metastasis (in our animal study) were compared using the *Student\'s t-test*. The associations of various clinicopathological parameters with the IHC scores for ASC, IL-1β, and CASP1 were evaluated using the Wilcoxon test. All statistical analyses were performed using the SAS software (version 9.1; SAS Institute Inc., Cary, NC). All patients received follow-up evaluations at our outpatient clinic until October 2011 or death. The survival time and various time intervals were calculated from the date of operation. Survival analyses were plotted using the Kaplan-Meier method, and differences were evaluated with the log-rank test. Univariate and multivariate regression analyses were performed under the Cox proportional hazard model, and were employed to define specific risk factors for survival status. All *p* values were two-sided, and statistical significance was accepted at *p* \< 0.05.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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